Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin
Research article published in Scientific reports (2017)
Abstract
Thrombin is a multifunctional enzyme with a key role in the coagulation cascade. Its functional modulation can culminate into normal blood coagulation or thrombosis. Thus, the identification of novel potent inhibitors of thrombin are of immense importance. Sculptin is the first specific thrombin inhibitor identified in the transcriptomics analysis of tick's salivary glands. It consists of 168 residues having four similar repeats and evolutionary diverged from hirudin. Sculptin is a competitive, specific and reversible inhibitor of thrombin with a Ki of 18.3 ± 1.9 pM (k on 4.04 ± 0.03 × 107 M-1 s-1 and k off 0.65 ± 0.04 × 10-3 s-1). It is slowly consumed by thrombin eventually losing its activity. Contrary, sculptin is hydrolyzed by factor Xa and each polypeptide fragment is able to inhibit thrombin independently. A single domain of sculptin alone retains ~45% of inhibitory activity, which could bind thrombin in a bivalent fashion. The formation of a small turn/helical-like structure by active site binding residues of sculptin might have made it a more potent thrombin inhibitor. In addition, sculptin prolongs global coagulation parameters. In conclusion, sculptin and its independent domain(s) have strong potential to become novel antithrombotic therapeutics.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin.
Por qué esto importa para la hirudoterapia
Este estudio caracteriza la sculptina, un nuevo inhibidor de trombina identificado a partir de la transcriptómica de glándulas salivales de garrapata, como un inhibidor competitivo, específico y reversible (Ki ~18,3 pM) que ha divergido evolutivamente de la hirudina y prolonga los parámetros globales de coagulación. El resumen distingue que la trombina consume lentamente la sculptina (perdiendo finalmente su actividad), mientras que el factor Xa la hidroliza, pudiendo cada fragmento polipeptídico inhibir la trombina de forma independiente. La relevancia para la ASH es indirecta: la sculptina es derivada de garrapata y no de sanguijuela, aunque se compara explícitamente con la hirudina y se discute dentro del panorama terapéutico antitrombótico. Advertencia: el estudio no involucra sanguijuelas y reporta hallazgos de laboratorio sin datos clínicos.
Citación
Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin
Iqbal A et al. · Scientific reports, 2017
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026